463 related articles for article (PubMed ID: 21502598)
1. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.
Ciccarelli N; Fabbiani M; Di Giambenedetto S; Fanti I; Baldonero E; Bracciale L; Tamburrini E; Cauda R; De Luca A; Silveri MC
Neurology; 2011 Apr; 76(16):1403-9. PubMed ID: 21502598
[TBL] [Abstract][Full Text] [Related]
2. Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia.
Ciccarelli N; Fabbiani M; Colafigli M; Trecarichi EM; Silveri MC; Cauda R; Murri R; De Luca A; Di Giambenedetto S
Antivir Ther; 2013; 18(2):153-60. PubMed ID: 23486721
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility.
Fabbiani M; Grima P; Milanini B; Mondi A; Baldonero E; Ciccarelli N; Cauda R; Silveri MC; De Luca A; Di Giambenedetto S
Antivir Ther; 2015; 20(4):441-7. PubMed ID: 25516553
[TBL] [Abstract][Full Text] [Related]
4. Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients.
Grima P; Fabbiani M; Ciccarelli N; Tana M; Farina S; Colafigli M; Mondi A; Cauda R; Di Giambenedetto S
J Infect; 2012 Nov; 65(5):439-46. PubMed ID: 22863903
[TBL] [Abstract][Full Text] [Related]
5. HIV-associated neurocognitive disorders: antiretroviral regimen, central nervous system penetration effectiveness, and cognitive outcomes.
Cross HM; Combrinck MI; Joska JA
S Afr Med J; 2013 Sep; 103(10):758-62. PubMed ID: 24079630
[TBL] [Abstract][Full Text] [Related]
6. Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy.
Garvey L; Surendrakumar V; Winston A
HIV Clin Trials; 2011; 12(6):333-8. PubMed ID: 22189152
[TBL] [Abstract][Full Text] [Related]
7. Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?
Vassallo M; Durant J; Biscay V; Lebrun-Frenay C; Dunais B; Laffon M; Harvey-Langton A; Cottalorda J; Ticchioni M; Carsenti H; Pradier C; Dellamonica P
AIDS; 2014 Feb; 28(4):493-501. PubMed ID: 24472743
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.
Winston A; Puls R; Kerr SJ; Duncombe C; Li PC; Gill JM; Taylor-Robinson SD; Emery S; Cooper DA;
HIV Med; 2012 Apr; 13(4):245-51. PubMed ID: 22151608
[TBL] [Abstract][Full Text] [Related]
9. HIV associated neurocognitive disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: a cross sectional study.
Kelly CM; van Oosterhout JJ; Ngwalo C; Stewart RC; Benjamin L; Robertson KR; Khoo S; Allain TJ; Solomon T
PLoS One; 2014; 9(6):e98962. PubMed ID: 24915530
[TBL] [Abstract][Full Text] [Related]
10. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.
Heaton RK; Clifford DB; Franklin DR; Woods SP; Ake C; Vaida F; Ellis RJ; Letendre SL; Marcotte TD; Atkinson JH; Rivera-Mindt M; Vigil OR; Taylor MJ; Collier AC; Marra CM; Gelman BB; McArthur JC; Morgello S; Simpson DM; McCutchan JA; Abramson I; Gamst A; Fennema-Notestine C; Jernigan TL; Wong J; Grant I;
Neurology; 2010 Dec; 75(23):2087-96. PubMed ID: 21135382
[TBL] [Abstract][Full Text] [Related]
11. Cognitive disorders in HIV-infected patients: are they HIV-related?
Bonnet F; Amieva H; Marquant F; Bernard C; Bruyand M; Dauchy FA; Mercié P; Greib C; Richert L; Neau D; Catheline G; Dehail P; Dabis F; Morlat P; Dartigues JF; Chêne G;
AIDS; 2013 Jan; 27(3):391-400. PubMed ID: 23079813
[TBL] [Abstract][Full Text] [Related]
12. Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART.
Tozzi V; Balestra P; Murri R; Galgani S; Bellagamba R; Narciso P; Antinori A; Giulianelli M; Tosi G; Fantoni M; Sampaolesi A; Noto P; Ippolito G; Wu AW
Int J STD AIDS; 2004 Apr; 15(4):254-9. PubMed ID: 15075020
[TBL] [Abstract][Full Text] [Related]
13. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
[TBL] [Abstract][Full Text] [Related]
14. Depression and neurocognitive performance in Portuguese patients infected with HIV.
Bragança M; Palha A
AIDS Behav; 2011 Nov; 15(8):1879-87. PubMed ID: 21598031
[TBL] [Abstract][Full Text] [Related]
15. Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up.
Gibbie T; Mijch A; Ellen S; Hoy J; Hutchison C; Wright E; Chua P; Judd F
HIV Med; 2006 Mar; 7(2):112-21. PubMed ID: 16420256
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients.
Fabbiani M; Ciccarelli N; Tana M; Farina S; Baldonero E; Di Cristo V; Colafigli M; Tamburrini E; Cauda R; Silveri MC; Grima P; Di Giambenedetto S
HIV Med; 2013 Mar; 14(3):136-44. PubMed ID: 22994586
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy.
Rahman AP; Eaton SA; Nguyen ST; Bain AM; Payne KD; Bedimo R; Busti AJ
Pharmacotherapy; 2008 Jul; 28(7):913-9. PubMed ID: 18576906
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
Bommenel T; Launay O; Meynard JL; Gilquin J; Katlama C; Lascaux AS; Mahamat A; Martinez V; Pradier C; Rouveix E; Simon A; Costagliola D; Abgrall S;
J Antimicrob Chemother; 2011 Aug; 66(8):1869-77. PubMed ID: 21636583
[TBL] [Abstract][Full Text] [Related]
19. Neuropsychological Assessment of 412 HIV-Infected Individuals in São Paulo, Brazil.
Gascón MRP; Vidal JE; Mazzaro YM; Smid J; Marcusso RMN; Capitão CG; Coutinho EM; Benute GRG; De Lucia MCS; de Oliveira ACP
AIDS Patient Care STDS; 2018 Jan; 32(1):1-8. PubMed ID: 29323557
[TBL] [Abstract][Full Text] [Related]
20. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.
Tozzi V; Balestra P; Salvatori MF; Vlassi C; Liuzzi G; Giancola ML; Giulianelli M; Narciso P; Antinori A
J Acquir Immune Defic Syndr; 2009 Sep; 52(1):56-63. PubMed ID: 19731418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]